MedTrace Logo

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT02024087 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-09-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and tolerability of dalantercept plus sorafenib in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose level of dalantercept in combination with sorafenib.

Conditions

  • Advanced Adult Hepatocellular Carcinoma

Interventions

DRUG

Dalantercept plus sorafenib

Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.

Sponsors & Collaborators

  • Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-04
Primary Completion
2017-07-05
Completion
2017-09-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02024087 on ClinicalTrials.gov